Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Correction

Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses

Cherrelle Dacon, Linghang Peng, Ting-Hui Lin, Courtney Tucker, Chang-Chun D. Lee, Yu Cong, Lingshu Wang, Lauren Purser, Andrew J.R. Cooper, Jazmean K. Williams, Chul-Woo Pyo, Meng Yuan, Ivan Kosik, Zhe Hu, Ming Zhao, Divya Mohan, Mary Peterson, Jeff Skinner, Saurabh Dixit, Erin Kollins, Louis Huzella, Donna Perry, Russell Byrum, Sanae Lembirik, Michael Murphy, Yi Zhang, Eun Sung Yang, Man Chen, Kwanyee Leung, Rona S. Weinberg, Amarendra Pegu, Daniel E. Geraghty, Edgar Davidson, Benjamin J. Doranz, Iyadh Douagi, Susan Moir, Jonathan W. Yewdell, Connie Schmaljohn, Peter D. Crompton, John R. Mascola, Michael R. Holbrook, David Nemazee, Ian A. Wilson, and Joshua Tan*

*Correspondence: tanj4@nih.gov

https://doi.org/10.1016/j.chom.2023.05.016

In Figure 6A, the authors discovered after publication that the neutralization NT50 values of two similar IGHV1-46/IGKV3-20 mAbs (COV30-14 and COV72-37) for several SARS-CoV-2 variants were switched due to a copying error. This correction does not impact the conclusions of the original paper. The affected NT50 values of the two mAbs only differed <2 fold. The authors regret the inconvenience caused by this error, which has been corrected in the original article online.

Figure 6A. COV30-14, COV72-37, and COV89-22 neutralize SARS-CoV-2 variants of concern and inhibit SARS-CoV-2 spike-mediated fusion (corrected)
Figure 6A. COV30-14, COV72-37, and COV89-22 neutralize SARS-CoV-2 variants of concern and inhibit SARS-CoV-2 spike-mediated fusion (original)